NCT06523699View on ClinicalTrials.gov

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Multiple Myeloma
Interventions
DRUG

Recombinant glycosylated human interleukin-7

Provided by RevImmune

DRUG

Melphalan

Standard of care

PROCEDURE

Autologous hematopoietic cell transplant

Standard of care

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Revimmune

INDUSTRY

lead

Washington University School of Medicine

OTHER